Corporate Vice President, Head of Global Marketing, Oncology @ Boehringer Ingelheim
Senior Health Economist @ Aventis Pharma
Group Product Manager @ sanofi-aventis
Post Graduate Diploma @
University of Aberdeen
Established strategic and commercial leader with over 15 years experience in the pharmaceutical sector. Unique skill mix spanning positions in health economics, sales and marketing at UK, Europe, EMEA & Russia and Global levels. Proven record of success in each role including product revitalisation, product launch, and most recently design and leadership of a stand alone Regional
Established strategic and commercial leader with over 15 years experience in the pharmaceutical sector. Unique skill mix spanning positions in health economics, sales and marketing at UK, Europe, EMEA & Russia and Global levels. Proven record of success in each role including product revitalisation, product launch, and most recently design and leadership of a stand alone Regional Business Unit with full accountability for profitability. Demonstrable impact of strategic decisions based upon a focus on pragmatism and execution directly into the field. Speciality care experience with specific focus on oncology.
Specialties: advertising, business case, business plans, delivery, development, economics, executive management, fast, finance, leadership, management, marketing, materials management, meeting facilitation, mentoring, microsoft access, msc, national institute for clinical excellence, nhs, novell, plan development, positioning, pricing, product management, promotional materials, protocols, public relations, quality, recruiting, sales, strategic, strategic planning, unique,
Corporate Vice President, Head of Global Marketing, Oncology @ Leadership of the corporate marketing team for the oncology TA (Therapeutic Area). Commercial leadership for the broad oncology business including early clinical development, in licensing and pipeline as well as launch and continuing commercialisation of assets. From August 2014 to Present (1 year 3 months) Ingelheim-am-Rhein, GermanyEMEA Head of Oncology Business Unit @ Leadership of a stand-alone business unit of over 100 employees responsible for pre-launch, launch and on going promotion of key oncology assets for the organisation. The role commands full accountability for profitability within a unique structure. Strategic and tactical responsibility requiring extensive interaction with senior management and senior external stakeholders including clinicians, payers, governments and others.
Product launch has been a Global success within the organisation and has been characterised by outstanding execution of market access and launch excellence strategies. Performance in launch year was the best across the Global organisation versus plan and this has been repeated in the second year of launch as well. From February 2010 to June 2014 (4 years 5 months) Hatfield, Hertfordshire, United KingdomMarketing Director Global (ex-US), Oncology Centre of Excellence @ Leading the Global (ex-US) launch of a new targetted therapy for breast cancer. Overall strategic lead and deliver core tactics for implementation at the local and Regional levels. In addition, preparing for the launch of a number of pipeline assets involving close interaction with R&D and market access as well as regulatory. From January 2008 to February 2010 (2 years 2 months) European Marketing Director, Oncology Centre of Excellence @ Responsible for the preparation and execution of the European launch of Tyverb (lapatinib). From August 2006 to December 2007 (1 year 5 months) Stockley Park, Uxbridge, UKEuropean Marketing Director, Oncology Centre of Excellence @ Haematology and Supportive Care
Commercial lead for strategic planning of new haematology franchise including in-licensing strategy
Preparation of launch activities for niche product for adult and paediatric lymphoma and leukaemia From June 2006 to August 2006 (3 months) Group Product Manager @ Taxotere®
Managing the overall brand across 5 indications and ensuring delivery against aggressive sales and growth targets. In my tenure as GPM, Taxotere has achieved market leadership in its defined segment for the first time in the brands UK history
Recruitment, management, and development of two senior product managers.
Launch of new adjuvant and combination breast cancer indications during merger and uncertainty to exceptional standards setting an example for other countries to follow
Development and management of Health Technology. Assessment strategy for the business unit including working with patient and political groups to help re-design the NICE appraisal process and secure a fast-track review of pivotal adjuvant Taxotere® indication.
Development and presentation of strategic and tactical plans for senior management that were used as a basis to secure additional investment.
Pivotal role in the development of the new Global strategy for the brand to address negative perceptions and pioneer of the first National Nurse Advisory Board to help develop and support execution of the strategy.
Lead for the first Global series of web casts with sales teams from around the world with development of simplified sales focussed messages. From November 2004 to June 2006 (1 year 8 months) Group Product Manager @ Leadership of the Taxotere franchise spanning all indications (breast, lung, prostate, gastric and head and neck) From 2005 to 2006 (1 year) Senior Product Manager @ Taxotere Breast From 2003 to 2005 (2 years) Senior Product Manager @ Taxotere® Breast
Development and implementation of strategy and pre-launch plan for adjuvant license due early 2005
Complete review and revival of metastatic indication with new campaign and materials launch within 6 weeks
Development, management, and implementation of commercial effectiveness initiatives for the oncology business unit in the UK including MAP (Maximising Advertising and Promotion), and customer segmentation and targeting models. From August 2004 to November 2004 (4 months) Senior Product Manager @ Taxotere® Lung
Delivering 74% annual patient sales growth in 12 months as product manager for lung indication
Complete brand revival including new positioning, marketing campaigns and development of a business case for the creation of a stand alone sales team that was accepted and implemented
Promotion of UK campaign that led to Globalisation of strategy and execution plan
Development of highly effective sales/medical/marketing matrix that is highly regarded within the organization
Innovator of new customer profiling and segmentation tool for oncology
Management and development of key opinion leaders and patient advocacy groups From May 2003 to July 2004 (1 year 3 months) Product Manager @ Delivering 23% year-on-year growth despite a negative NICE recommendation in core indication for Campto
Management of numerous agencies (advertising, medical education and public relations) as well as working with patient charities and NHS bodies
Highly effective relationship with Global marketing and medical - utilizing opportunities for the UK affiliate including facilitating the use of UK KOL speakers at international meetings
Initiation and management of NICE re-review for treatments working in association with competitor companies and other external stake holders
Development of strategic plan for Scotland and local territories in direct association with sales force
Effective handover and mentoring of new product manager
Presentation and implementation of UK campaign in other affiliate countries and sharing best practice From May 2002 to May 2003 (1 year 1 month) Product Manager @ Campto - Colorectal Cancer and Taxotere - Lung Cancer From 2002 to 2003 (1 year) Sales Representative @ To enhance my effectiveness as a new marketer without prior sales experience I was the representative for the local cancer center. This involved the development and execution of a business plan; KOL development action plan and gaining increased usage of Campto for colorectal cancer. From May 2002 to October 2002 (6 months) Senior Health Economist @ Responsible for extensive health economic support for oncology, CNS and osteoporosis products. Support provided includes development and dissemination of health economic outcomes relating to cost-effectiveness and budgetary impact, support for submissions and implementation of NICE guidance, sales force training, liaison and development of creative economic outcomes with key opinion leaders
Extensive experience with NICE including development of submission, appeal and post-recommendation audit
Responsible for a number of new initiatives including development of a health economic advisory board to provide a forum for discussion and opportunity to 'test' concepts with independent experts. Also responsible for an educational series on health economics aimed towards health care practitioners
Development of web-based training programme in health economics for health professional From January 2001 to May 2002 (1 year 5 months) Senior Health Economist @ All market access activities related to oncology and speciality care products From 2001 to 2002 (1 year) European Pharmacoeconomist @ European Pharmacoeconomist
Sole responsibility for pharmacoeconomic (PE) support to key European business units
Provide means of communication of PE issues between the US and Europe
Work across functions to develop product specific PE strategy and deliver upon it within the specified timeline
Develop study protocols and complete analysis to provide insights to key internal and external users of PE
Promote PE use in Europe amongst different departments and provide insight in to national guidelines for PE and its value in launch and promotional activities
Work with large datasets (GPRD, PHARMO, VHS) to combine PE data with epidemiology and provide meaningful analysis
Use PE models to produce technical reports including end-points for cost-effectiveness and quality of life implications From October 1998 to January 2001 (2 years 4 months)
MBA, Health Economics @ Keele University From 2003 to 2006 Post Graduate Diploma, Health Economics and Management @ University of Aberdeen From 2001 to 2002 MSc, Finance & Investment @ Brunel University London From 1996 to 1997 BSc Economics, Economics, Finance and Investment @ Brunel University Uxbridge, Middlesex From 1993 to 1997 BSc (Hons), Economics @ Brunel University From 1993 to 1996 Uday Bose is skilled in: Design, build and..., Accountability for P&L..., Global, Regional,..., Launch excellence (2..., Management (all levels..., Clinical Development, Experience working..., Asset Life Cycle..., Oncology, Market Access, Strategy, Pharmaceutical Industry, Business Planning, Product Launch, Product Management, Hematology, Pharmaceutical Sales, Health Economics, Marketing Management, Strategic Planning, Business Strategy, Global Marketing, Marketing, Pricing, Healthcare, Medical Education
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension